Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: New vaccines against tuberculosis (TB) are urgently needed because the only available vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), fails to protect against pulmonary TB in adults. The recombinant ΔureC hly+ BCG (rBCG) is more efficient than parental BCG (pBCG) against pulmonary TB in preclinical studies and has proven safe and immunogenic in phase I clinical trials. METHODS: In an attempt to identify the mechanisms underlying the superior protection of rBCG, we compared the immune responses elicited after vaccination and subsequent aerosol infection with Mycobacterium tuberculosis (MTB) in mice. RESULTS: We demonstrate that both rBCG and pBCG induce marked type 1 cytokine responses, whereas only rBCG elicits a profound type 17 cytokine response in addition. We observed earlier recruitment of antigen-specific T lymphocytes to the lung upon MTB infection of rBCG-vaccinated mice. These T cells produced abundant type 1 cytokines after restimulation, resulting in 10-fold reduced bacterial burden 90 days after infection. CONCLUSIONS: Our findings identify a general immunologic pathway for improved vaccination strategies against TB that can also be harnessed by other vaccine candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 5×
“IL-22–producing cells have been identified in patients with TB, but these cells seem to be distinct from IL-17–producing cells [18].”
BackgroundInfluentialTrunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114
Innate immune recognition of infected apoptotic cells directs TH17 cell differentiation
Torchinsky, M. B., Garaude, J., Martin, A. P., & Blander, J. M. (2009) · Nature · doi:10.1038/nature07781 · Cited by 364
Cited by
Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
Ottenhoff, T. H. M., & Kaufmann, S. H. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002607 · Cited by 455
Self-citationCytokines and Chemokines in Mycobacterium tuberculosis Infection
Domingo-Gonzalez, R., Prince, O., Cooper, A., & Khader, S. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0018-2016 · Cited by 404
In search of a new paradigm for protective immunity to TB
Nunes-Alves, C., Booty, M. G., Carpenter, S. M., Jayaraman, P., Rothchild, A. C., & Behar, S. M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3230 · Cited by 315
What Have We Learnt about BCG Vaccination in the Last 20 Years?
Dockrell, H. M., & Smith, S. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01134 · Cited by 259
Metadata
- Authors
- Desel, C., Dorhoi, A., Bandermann, S., Grode, L., Eisele, B., & Kaufmann, S. H. E.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 204
- Issue
- 10
- Pages
- 1573-1584
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2123240902
- Cited by
- 159
- References
- 5
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.